| Literature DB >> 28614803 |
Lei Yu1, Ruoke Wang2, Fei Gao2, Min Li3, Jianying Liu4, Jian Wang1, Wenxin Hong1, Lingzhai Zhao1, Yingfen Wen1, Chibiao Yin1, Hua Wang2, Qi Zhang2, Yangyang Li2, Panpan Zhou2, Rudian Zhang4, Yang Liu4, Xiaoping Tang1, Yongjun Guan1, Cheng-Feng Qin5, Ling Chen6,7, Xuanling Shi2, Xia Jin3, Gong Cheng4, Fuchun Zhang1, Linqi Zhang2.
Abstract
Zika virus (ZIKV) is an emerging mosquito-transmitted flavivirus that shares a considerable degree of homology with dengue virus (DENV). Here, we examined longitudinal antibody response against ZIKV during natural infection in 2 convalescent individuals. By decomposing the antibody recognition into DI/DII and DIII of the E glycoprotein, we showed their development in humans followed a spatiotemporal hierarchy. Plasma binding to DI/DII appeared to peak and wane during early infection with extensive cross-reactivity with DI/DII of DENV. Binding to DIII, however, peaked early but persisted months into the infection without detectable cross-reactivity with DIII of DENV. A clear trend of increase in DIII-specific neutralizing activity was observed over the course of infection. mAbs isolated during early infection are largely DI/DII specific, weakly neutralizing, and highly cross-reactive with DENV, while those from later infection are more diverse in recognition, potently neutralizing, and ZIKV specific. The most potent neutralizing mAb targeting the DIII provided 100% protection in mice from lethal ZIKV infection and could therefore serve as a promising candidate for antibody-based therapy and prevention. The dynamic features unveiled here will assist us to better understand the pathogenesis of ZIKV infection and inform rational design of vaccines.Entities:
Keywords: Immunology; Infectious disease
Year: 2017 PMID: 28614803 PMCID: PMC5470883 DOI: 10.1172/jci.insight.93042
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708